|Trade names||Ortho Evra, Xulane, Evra|
|AHFS/Drugs.com||Professional Drug Facts|
|Chemical and physical data|
|Molar mass||623.878 g·mol−1|
|3D model (JSmol)|
Norelgestromin/ethinylestradiol, sold under the brand name Ortho Evra among others, is a contraceptive patch containing the progestin norelgestromin and the estrogen ethinylestradiol. As of December 2016, the product Ortho Evra has been discontinued in the U.S. while the product Xulane continues to be marketed.
The most common side effects include headache, nausea (feeling sick), breast tenderness, and irregular uterine bleeding.
Norelgestromin/ethinylestradiol was approved for medical use in the United States in November 2001, and in the European Union in August 2002.
Norelgestromin/ethinylestradiol is a transdermal patch (a patch that delivers a medicine across the skin). For the first three weeks of the menstrual cycle a new patch should be applied every week, followed by a fourth week, which is patch-free. The patch-free interval must not be longer than seven days; otherwise, additional non-hormonal contraceptive methods must be used, such as condoms. Transdermal patches must always be applied on the same day of the week to the buttock, abdomen (belly), upper arm or upper back. The same area of skin should not be used for two consecutive patches. Norelgestromin/ethinylestradiol may work less well in women weighing 198 pounds (90 kg) or more.
In the United States norelgestromin/ethinylestradiol is indicated for the prevention of pregnancy in women with a BMI < 30 kg/m2 for whom a transdermal delivery system is an appropriate method of contraception.
In the European Union, norelgestromin/ethinylestradiol is indicated for use as female contraception.
Society and culture
The cost in the U.S. of this medication is $46 (USD) for 1 transdermal extended release film 35 mcg-150 mcg/24 hr
- Combined injectable contraceptive
- Contraceptive vaginal ring
- Oral contraceptive formulations
- List of combined sex-hormonal preparations
- ↑ "Evra Product information". Health Canada. 21 June 2018. Archived from the original on 18 February 2020. Retrieved 17 February 2020.
- ↑ "Evra transdermal patch - Summary of Product Characteristics (SmPC)". (emc). 26 June 2020. Archived from the original on 24 October 2020. Retrieved 4 July 2020.
- ↑ 3.0 3.1 3.2 3.3 "Xulane- norelgestromin and ethinyl estradiol patch". DailyMed. 7 April 2020. Archived from the original on 6 July 2020. Retrieved 4 July 2020.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 "Evra EPAR". European Medicines Agency (EMA). Archived from the original on 12 November 2020. Retrieved 4 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "Ortho Evra (norelgestromin/ethinyl estradiol transdermal system) Initial U.S. Approval: 2001". DailyMed. 12 July 2018. Archived from the original on 5 July 2020. Retrieved 4 July 2020.
- ↑ "Ortho Evra: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 5 July 2020. Retrieved 4 July 2020.
- ↑ "Drug Approval Package: Ortho EVRA (Norelgestromin/Ethinyl Estradiol Transdermal System NDA #21-180". U.S. Food and Drug Administration (FDA). Archived from the original on 5 July 2020. Retrieved 4 July 2020.
- ↑ "Ortho Evra Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 7 September 2015. Retrieved 30 March 2021.
- "Ethinyl Estradiol mixture with norelgestromin". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 9 February 2021. Retrieved 19 January 2021.
- Pages using duplicate arguments in template calls
- Use dmy dates from February 2020
- Articles with invalid date parameter in template
- Drugs with non-standard legal status
- Chemicals that do not have a ChemSpider ID assigned
- Infobox drug articles with contradicting parameter input
- Articles without EBI source
- Multiple chemicals in Infobox drug
- Multiple chemicals in an infobox that need indexing
- Chemical articles with multiple CAS registry numbers
- Drug has EMA link
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Articles with hatnote templates targeting a nonexistent page
- Portal templates with all redlinked portals
- Combined hormonal contraceptives
- Transdermal patches
- All stub articles
- Genito-urinary system drug stubs